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ABSTRACT
The first discussions relating to the regulation of recombinant DNA
technology in the UK occurred in 1970, and were independent of
similar discussions happening in the US from 1973. UK regulatory
authorities were differently motivated by the range of concerns around
risk posed by the new technology. UK authorities implemented a
framework that was informed by a specific culture that had roots in
scientific and laboratory work practices. The paper reflects on the early
close relationships between UK biotechnology industry and university
laboratory spaces, and the central concern around laboratory safety and
workers rights.
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The story of the birth of biotechnology and how regulation evolved in the life science industry has
been variously told. The history relates to us, the early gene splicing experiments from 1969, the
establishment of pioneering firms such as Cetus and Genentech (1971 and 1976) and the first discus-
sions of regulation in 1975 that ended a moratorium in the US, and allowed experimentation to
continue.
In Jasanoff’s 1993 paper American Exceptionalism and the Political Acknowledgement of Risk,
Jasanoff writes that ‘while the US process for making risk decisions impressed all observers as
costly, confrontational… and unusually open to participation’, in Europe ‘policy decision about
risk remained, as before, the preserve of experienced bureaucrats and their established advisory net-
works’ (63, 66). Rather than adding to ample literature on the US case with a detailed historiography,
this work seeks to understand how the rather different regulatory culture in the UK, identified by
Jasanoff and others, came to be so distinct in its very early inception. I examine particular events
in the UK at a crucial time period from 1970 to 1978 and demonstrate how epistemic communities
and the framing of risk underpin the establishment of a fundamentally distinct regulatory culture.
In the UK, the political space from which governance structures evolved, was dominated by the
close relationship between government, industry and trade union representatives. This paper makes
an original contribution in understanding how, in the era of progressive public administration, this
high trust relationship (Hood 1995) was reinforced as incidents in laboratories raised a range of con-
cerns. These concerns were prioritised differently in the US, where the tension between industry and
academia has largely become the focus for analysis. Thus whilst recognising a need to implement
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regulation around biotechnology, the UK did not simply follow a lead as set by the US, but rather
implemented a framework that was informed by its own specific community and culture that had
roots in UK scientific and laboratory work practices. The question this paper will answer is, how
was a distinct regulatory culture around biotechnology regulation formed in the UK from 1970 to
1980?
This paper will first set out the analytical concept ‘epistemic community’ and its machinery.
Second, the paper describes the events that led to the drafting of the first regulations for genetic
manipulation in the US. I draw out two themes evident in this broad history: incidents around
health and safety and the relative relationship between stakeholders in the policy making
process. The central part of this paper will apply these two themes to the UK context, to frame rel-
evant and detailed descriptions of particular unique events and people. Finally, the paper discusses
how the concept of epistemic community may be useful in understanding how a distinct regulatory
culture was formed.
2. Epistemic communities
Knorr-Cetina (1999, 1) defines epistemic culture as ‘those amalgams of arrangements and mechan-
isms bonded through affinity, necessity and historical coincidence – which, in a given field, make up
how we know what we know’. Knorr Cetinas definition of ‘culture’ is rooted in her study of practice
in laboratories. It refers to the aggregate patterns and dynamics in the practice of experts.
Experts who share a culture in a given field and are involved in the production of knowledge, have
been described by Knorr-Cetina (1981) and later by Haas (1992), as an epistemic community. Accord-
ing to Haas (1992, 3) an epistemic community is ‘a network of professionals with recognised exper-
tise and competence in a particular domain and an authoritative claim to policy-relevant knowledge
within that domain or issue-area’. Differently to Lave and Wengers communities of practice concept,
Haas uses epistemic community to understand how policy coordination happens in areas with tech-
nical and scientific uncertainty (Akrich 2010). The notion of epistemic community has been widely
applied to the analysis of regulatory practice in the life sciences (see for example Jansen and
Roquas 2005; Kingiri 2011; Meghani and Kuzma 2011). These authors outline how, in the face of rela-
tively high uncertainty and risk, experts are drawn into the policy space as a key part of the policy
making machinery.
What interests Knorr Cetina, and what is most important to this paper, is less the production of
knowledge, but more the construction of ‘the machineries of knowing’, both social and technical.
According to Knorr-Cetina (1999), knowledge construction is shaped by and is inseparable from
the machinery used for its production. Epistemic machinery is comprised of those methodologies,
techniques, tools and instruments used in our knowledge production and distribution. The machin-
ery, and the culture that surrounds it, is thus located in the micropractices of laboratories (Knorr-
Cetina 2007).
What is also relevant to this paper, is how this body of theory might consider shared experiences
and significant historical events. It follows that if an event is so significant that it causes change in the
micropractices of all laboratories in a given field (e.g. an event that demonstrates considerable risk to
health and safety), this in essence, is a demonstrable change to an epistemic culture. The argument is
put forward that the emergence of a new regulatory framework in the UK was driven by realities and
events and also their perception and interpretation by the epistemic machinery. In other words, how
experts at the forefront in dealing with incidents and accidents in the laboratory, were called upon as
key experts in an uncertain and emerging regulatory environment.
Of special interest then is Grundmann (1996) critique of Haas’s concept of epistemic community.
While Hass posits that the experts making up an epistemic community share common values and
believe in the same relationships and tests of truth, Grundmann questions the idea that consensus
making is an inherent, non-conflictive characteristic of epistemic communities. For Grundmann, con-
sensusal knowledge is not a necessary condition for epistemic communities to exist and work. The
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relevance of this critique is in understanding how the events that unfolded concerning safety in bio-
technology laboratories might have been variously interpreted and acted on by the policy making
community. Grundmann adds that power must not be ignored and the actors most likely to instigate
change are those that are able to mobilise resources.
3. The birth of biotechnology and regulatory policy in the United States
Concerns around the safety of laboratory workers framed the earliest of discussion in the US. In 1971,
Paul Berg led a team at Stanford University whowereworking on splicing lambda phage DNA into the
DNAof the simian virus SV40. Thisworkwas first donebyBergs student JanetMertzwho,whilemaking
good progress and optimising the technique, attended a tumour virus workshop at Cold Spring
Harbour led by a tumour virologist Robert Pollack (Crotty 2001, 90). Pollack expressed huge
concern about the intendedwork to bothMertz and Berg, describing it as dangerous and outrageous.
Heperceived risk to laboratoryworkers if recombinants containing tumourgenes from the SV40 found
theirway into cultures of E. coli, thebacterial speciesmostwidely used in laboratory research and com-
monly inhabiting the human intestinal tract (U.S. National Library of Medicine, year not known).
As momentum gathered, these concerns appeared to be echoed through the community of
scientists involved. As a result of these concerns Berg and others convened a meeting to assess
the risks of working with tumour viruses and recombinant DNA. The meeting held in January
1973 at the Asilomar Conference Center, California, was sponsored by the National Institutes of
Health and the National Science Foundation. The meeting concluded with several recommendations
to changes in laboratory practice being made, which included periodically monitoring researchers
who work with tumour viruses for infection, to prohibit pipetting by mouth, and to use laminar
flow hoods during all manipulations involving potentially infectious material (Berg and Mertz
2010). The meeting was attended by around 100 scientists and there was no press coverage.
In 1973 Herbert Boyer, of the University of California at San Francisco, and Stanley Cohen, at Stan-
ford University, were working to advance the work of Paul Berg. Using ECO RI, they combined two
antibiotic-resistant genes in a plasmid and placed it into E. Coli. The announcement of this achieve-
ment was made during the 4th day of another conference, The Gordon conference in June of that
year, by Herbert Boyer, against the advice of his absent colleague, Stanley Cohen. The work of Cohen
and Boyer no doubt placed Berg in an awkward position as he called for a cautious and slow
approach. The proceedings, attended by 143 people were quickly thrown into disarray and the
remainder of the conference focussed on this announcement and addressing the repercussions.
Concerns were voiced at this conference, including the risk of cancer for laboratory personnel hand-
ling and scaling up potentially cancer causing viruses, and parallels were drawn with the early years
of biological weapons and atomic energy with secrecy surrounding a build-up of nuclear arms
(Morgan 2005). A letter to the National Academy of Sciences and the institute of Medicine was
drafted, summarising the promises and risks of the new recombinant technology. It also advised
that a committee be established to recommend actions and governance for this new science. The
letter appeared in the magazine Science in September 1973.
Maxine Singer who chaired the Gordon conference, recommended that Berg head that commit-
tee. He duly organised a small meeting in April 1974 to discuss what the next steps should be. The
committee concluded that scientists across the world should enact a voluntary moratorium on the
science, while they deliberated the benefits, risks and governance. They also agreed that as far as
possible, decision making should be kept within the professional boundaries of the scientific com-
munity (Morgan 2005, 8) and an international meeting should be held (Harron 1983).
The ‘Berg letter’ written by Berg and 10 others, in July 1974 and published in Science, requested
that the National Academy of Sciences give attention to rDNA research and its potential biological
hazards. They suggested scientists throughout the world place a moratorium on rDNA research and
the NIH should establish an advisory committee charged with developing procedures and guidelines
for rDNA experiments (Morgan 2005). The NIH did take up a leadership position and in October 1974
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established the Recombinant DNA molecule Advisory Committee (RAC) to study the potential bio-
hazards presented. And so while concerns grew and became established, the US policy making com-
munity started off as a close knit group of university academicians that did not extend beyond those
immediately involved in the production of the science.
The issue quickly took on an international dimension and an international meeting that was
organised in response to the recommendation by Bergs committee, also in Asilomar (known as Asi-
lomar II), took place in February 1975. It was attended by 90 scientists from the US, 60 scientists from
outside the US, 16 reporters and a handful of lawyers. There were no representatives from wider
society. Science For The People were a prominent advocacy group in the eye of the public at the
time and were not in favour of recombinant DNA experimentation. They drafted a letter to the con-
ference, which was circulated, but not discussed. David Baltimore opened the conference impressing
upon the community gathered, the need for scientists to take responsibility and to self-regulate. The
groups of lawyers in attendance strongly echoed this position and in addition, advised that other
federal agencies be involved, including the Department of Labor, the FDA, the EPA, the Centres
for Disease Control and Infection. The lawyers suggested that if the scientific community at the
meeting did not arrive at a consensus position and a proposition for a system of self-regulation,
federal agencies would take the lead in regulating the new science. Not only this, but publics
would likely become involved and this would lead to restrictions in scientific experimentation.
The dissenting voices of scientists, those that attempted to express concern about the possible
social uses of genetic engineering, were effectively silenced, and the issues were reduced to a tech-
nical question of containment (Wright 1998).
A draft statement was circulated on the last morning of the conference, written by the organising
committee on the previous night. Conference attendees voted on various pieces of the statement. It
was finally agreed that the moratorium should be lifted and work should proceed, with safeguards
and with some exceptions. The provisional statement was released at a press conference on the Feb-
ruary 28 1975. It was immediately adopted by the NIH Recombinant DNAMolecule Program Advisory
Committee (John Hopkins University 2018).
In May of 1975 the RAC met to frame the guidelines for rDNA research and July, an RAC subcom-
mittee was held to draft the provisional guidelines. The NIH advisory committee invited public com-
ments in November 1975 and then published its own guidelines. Many doubts and fears from the
public and from scientists were expressed to the committee during the consultation period.
Wright (1998) describes the regulatory arena up until the end of 1975, as one that was largely
controlled by, and responsive to scientific elites. Wright (1994) suggests that US public participation
before 1976 was largely an illusion, but in 1976 there was a change in direction, or a ‘second phase’
in policy making as public concern and controversy erupted (Wright 1998).
The Congress did not play a major role in the early development of rDNA guidelines. The House of
Representatives committee on Science andTechnology, and specifically, its subcommittee on Science,
Research and Technology, kept pace with the issue by preparing a series of reports. Following the Asi-
lomar conference, in April 1975 (and again in September 1976), the senate committee on Labour and
PublicWelfare, specifically the Subcommittee onHealth, held hearings on rDNA technology. It was not
until 1977 however that the Congress decided to take direct action and introduced 16 bills to regulate
recombinant DNA research. The bills called for the development of bacteria and plasmids that could
be prevented from escaping from the laboratory environment. None of the bills passed however.
It is argued that the regulatory culture in the US was shaped by the wider political context in
which these discussions were taking place. Krimsky (2005) for example discusses a number of rel-
evant factors including the birth of the environmental movement in the 60s and the rise of political
activism in the 1970s that the US government saw fit to respond to. The 1960s sunshine laws and
1970s Freedom of Information Act in the US required meetings of agency officials to be open to
press and public. The Environmental Protection Agency was created in 1970, and the Office of Tech-
nology Assessment in 1972. Technology assessment and environmental impact was introduced into
Federal programmes and a new sensibility toward government ethics followed the post Watergate
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era. Importantly there were revelations about unethical human experiments involving radiation, psy-
chtropic drugs and biological agents (e.g. the Tuskergee Syphillis study). A new generation of biol-
ogists completed their studies during the peak of the Vietnam War and the signing of the biological
weapons convention (1972) having studied under the guidance of professors who spoke about the
role of physics in the nuclear arms race (Krimsky 2005). Krimsky (2005) suggests that over the course
of Asilomar I and II, discussion of risk turned from informed consent of the lab worker to informed
consent of the community.
The development of private interests in the late 1970s further acted to frame risk and shape
policy. Scientists in the US, attracted by the potential for profit and intellectual freedom, were the
first to spin out of their universities, establishing companies like Genentech in 1976. From the first
demonstration of bacterial expression of somatostatin gene in 1977, multinational and venture
capital firms began to invest in these small genetic engineering firms. Once it became clear that con-
gressional interest could be blocked, the scientific community with the support of industry began to
push for a reversal in policy. And this happened from 1979 onward as the practice of ‘containment of
unknown hazard’ was gradually replaced in policy by the claim that genetic engineering posed ‘no
extraordinary hazard’ (Wright 1998).
The US case highlights two themes that can be applied to the UK. Firstly the nature of the policy
making elite in this narrow field and its relationship to other policy groups, industrial partners and
the wider political context. These relationships in turn impact the way that risk is framed, which is the
second theme discussed in the UK case below.
4. Biotechnology and regulatory policy in the UK
4.1 Initial framings of risk
In the early 1970s, a group of European ‘forerunner’ countries quickly opted for a voluntary
approach based on NIH guidelines. There were differences between European neighbours
however. Some left the solution to technical experts and others opted for a more inclusive approach,
soliciting view from other sectors of society. Torgeson (2002) specifically note two things of particu-
lar relevance in the UK. Firstly there was very little significant wider public concern or debate at this
time, even less than occurred in the US. British policy was focused on occupational hazards and the
debate around the ‘epidemic pathogen’ that happened in the US, was not seen as relevant (Wright
1998). Secondly, the initial guidelines adopted in the UK, preceded those produced by the NIH. The
remainder of this paper is dedicated to understanding how guidelines in the UK were established
given that Britain did not use as a basis, the guidelines produced by the NIH.
The literature charting governance of UK biotech often takes as its starting point the work of the
Ashby committee and its report published in 1974 (see Gottweiss 1998). While regulatory policy and
policy makers in the UK no doubt closely followed proceedings in the US, I argue that the various
committees and working groups central to policy making were drawn from an epistemic community
that by that time, had already established a risk framing perspective that had more to do with acci-
dents and incidents in UK laboratories.
A committee on health and safety at work was appointed in May 1970 by Barbara Castle then
secretary of state for employment and productivity for the Labour government. The committee
was chaired by Lord Alfred Robens, a trade unionist and Labour politician. The committee reported
in June 1972. The Robens report opens with the statement ‘Every year something like 1,000 people
are killed at their work in this country. Every year about half a million suffer injuries in varying
degrees of severity’ (Robens and Robens 1972, 1). It controversially concluded that ‘apathy’ by
employers and employees was primarily to blame. Furthermore, excessive or overly detailed regu-
lation could promote apathy and a more effective self-regulating system was needed with the
burden falling on employers and workers.
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Despite the long term trend in the improvement of working conditions and the general fall in
fatalities due to improved medical care etc., the report suggests a radical rethink of the system as
a whole because of toxic and dangerous new chemical substances. The report discusses particular
cases including asbestos (and the link to cancer) and though its link to health and safety at work
is not made clear, also the case of thalidomide.
Chapter 14 of the report specifically addresses safety in research institutes and universities. The
report sought to expand health and safety legislation from conventionally ‘dangerous’ industries
such as coal mining, to include all workplaces. Listed in the appendix of the aforementioned
report, amongst those that submitted evidence for the report are various unions and lecturers in
charge of university-affiliated occupational hygiene laboratories. Analysis of the Robens Commit-
tee’s work by Sirrs (2015), finds an emphasis on consensus and ‘tripartism’ (the involvement of gov-
ernment, industry and trade union representatives). Though there was much criticism at the time of
Robens faith in voluntary-effort and self-regulation the Trade Union Congress and the Confederation
of British Industry still felt it represented an advance over the existing system. Sirrs argues that the
principles established by the Robens report (those of self-regulation and onus on the individual
worker and employer to mitigate risk) continued to underpin regulatory frameworks as they
evolved in the UK.
4.2 Incidents and outbreaks; the concerns of unions
In March 1973, a graduate laboratory technician employed at the London School of Hygiene and Tro-
pical Medicine was admitted to St. Mary’s Hospital, suffering from suspected meningitis or glandular
fever. She was admitted to an open ward where she came into contact not only with other patients,
but with two visitors who tragically died. The technician had contracted Smallpox and had passed it
on in the ward setting (Marsden 1974).
Sir Keith Joseph, the Conservative Secretary of State for Health, appointed the Cox committee to
hold an inquiry into the origin of the smallpox outbreak. The preliminary meeting took place in May
1973 and the report from this working party was published in 1974 under the Labour Government
Secretary of State for Health, Barbara Castle. The report specifically recommended: 1. The establish-
ment of a permanent committee of experts (i) to designate a list of pathogens, laboratory work with
which constitutes a major threat to public health; (ii) to maintain a register of departments where
work with designated pathogens is being undertaken; (iii) to formulate and regularly review a
code of practice necessary for the safe conduct of all such procedures; and (iv) to have power to
ensure that the code is followed (Marsden 1974). A code of practice was implemented: the Code
of Practice for the Prevention of Infection in Clinical Laboratories and Post-mortem Rooms (com-
monly known as the ‘Howie Code, after its chairman James Howie) was developed (Cottam 1994).
Meanwhile, The Health and Safety at Work Act 1974 (UK Gov 1974) came into force. It
implemented many of the recommendations advanced by the Robens report. The HSWA was
described as ‘a bold and far-reaching piece of legislation’ by HSE’s first Director General, John
Locke. Where earlier regulations applied only to factories, the HSWA applied to universities too.
The Act established the Health and Safety Commission (HSC) for the purpose of proposing new regu-
lations, providing information and advice and conducting research. HSC’s operating arm, the Health
and Safety Executive (HSE) was formed shortly after in order to enforce health and safety law. The
HSC in its first few months was concerned with asbestos, construction, dusts, ionising radiation,
lead, noise, vinyl chloride and importantly, genetic manipulation. The scientific community in the
UK, in 1974 would have been aware of the discourse around genetic manipulation and safety con-
cerns at the international level, though there is a lack of evidence that can be drawn upon to sub-
stantiate this claim. Union membership was on the rise and academic unions were concerned,
perhaps due to the laboratory incidents that are described below.
While the Cox committee was set up to investigate the 1973 incident, the government set up
another committee in 1975 under the chairmanship of Sir George Godber to examine wider
6 F. HUZAIR
questions of how dangerous pathogens should be regulated. The Godber Committee recommended
that a permanent expert committee, the Dangerous Pathogens Advisory Group (DPAG), be set up
under the health and safety Executive, to advise the government on safety measures and to inves-
tigate the suitability of specific laboratories for handling particular pathogens (McGinty 1979). It was
proposed the group would report to the department of Health and Social Services and be granted
statutory power under the health and safety at work act (Leggett and Sleigh 2017).
In August 1978, there was another outbreak of smallpox, this time at the University of Birming-
ham which caused the death of a medical photographer who worked there. Before the conclusion
of the investigation into how the virus was transmitted was reported to the DHSS (Anonymous
1978a) there were a number of other controversies. These included criticism from the trade
unions over safety standards at the university. Also the question of why the laboratory was given
approval to work with small pox by the Dangerous Pathogens Advisory Group in 1976, despite
refusal from the WHO to allow these activities after December of that year. The conclusions of the
report (by R. Shooter a member of the board of the public health laboratory service), were well pub-
licised and the report was published in July 1980. The Shooter team recognised the legitimate inter-
national dimension of the concern, and took steps to demonstrate this. The WHO sent an observer to
participate in the first three meetings of the investigation, and this placed the WHO on a par with the
DHSS and the Trades Union Congress, as legitimate bodies weighing in on the issue (Sims 1988). The
report highlighted the numerous failings within the laboratory itself in not complying with the
voluntary standards as laid down by DPAG (Anonymous 1978b).
4.3 Regulation on genetic manipulation; the closed and narrow nature of UK policy circles
As news began filtering through from the US on Asilomar II, a second line of regulatory authority
began to develop in the UK in parallel with the HSE and DPAG. The Advisory Board for the research
councils (the University Grants Committee, under the jurisdiction of the Department of Education
and Science) set up a working party of senior scientists under Lord Ashby, a botanist who held pos-
itions at Cambridge University and on the Royal Commission on Environmental Pollution just prior to
this work. The boardwas to make an assessment of the potential benefits and potential hazards of
techniques which allow the experimental manipulation of the genetic composition of micro-organ-
isms. The report of the working party was published in January 1975. It stated that members were
‘convinced that the hazards are less serious than some of us had first thought’ and that work should
go ahead provided precautions are taken. The Ashby report recommended that safety controls be
voluntary (Gibson 1986).
Following Ashby, another working party set up in August 1975 by the Department of Education
and Science, chaired by professor Robert Williams (bacteriologist and director of the public health
laboratory service), was tasked with preparing a code of practice for work involving genetic manipu-
lation (Gibson 1986). In August 1976, the party published its recommendations (Lewin 1976). Its
document stated that ‘no genetic manipulation experiment should be undertaken in containment
conditions less stringent than those used for work with common pathogens’. It was this committee
that specified a tiered categorisation of four containment levels for different types of genetic
manipulation (Leggett and Sleigh 2017). The Williams Report did not attempt to be absolutely
specific about the acceptability of experiments, suggesting each proposal be assessed individually
with categorisations and regulation becoming more specific with time and experience. This ‘case
law’ approach was very different to the system of approval as was emerging in the US and was
favoured by the European Science foundation because of it flexibility.
The Williams report was published after three months, the same day as the above mentioned
report produced by the HSC. The two documents were very much opposed. Not only did the HSC
attempt to draw up a specific description of genetic manipulation, it decided to include the tra-
ditional tool of genetics, which had already been in use for many years without hazard. An article
in the New Scientist in October 1976 reported:
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With the Ashby and Williams report behind them researchers would have been all set to gear up for the
undoubtedly fruitful research that lies ahead. But the HSC’s consultative document has put a stop to that,
and unmistakable gloom, anger and fear has settled over the country’s genetic manipulators. With the Williams
report the researchers could feel a road sympathy; by comparison the HSC’s document is an alien being… its
contents appear to take the whole genetic engineering debate right back to square one…Worse, it appears to
have been written by someone having no idea of what genetic engineering is about. (Lewin 1976, 220)
Despite the contestation over regulatory space, the Genetic Manipulation Advisory Group
(GMAG) was set up, from the recommendations of the Williams reportand met for the first time in
December 1976. GMAG should be, according to the Williams report, an independent advisory
body, granted powers under the Health and Safety at work act which would require laboratories
to submit their proposals to the group (Lewin 1977). GMAG would then advise researchers on the
categorisation of the work and on the relevant code of practice. The details of experiments
should also, according to the Williams report, be submitted to the Health and Safety Commission
which would, in turn, receive technical advice from GMAG (Cripps 1981). An entirely closed shop
was not intended and GMAG aimed to be broadly representative. It therefore included eight scien-
tific and medical experts, four members representing public interests, four members of the TUC, two
representatives of the CBI, and one member representing university vice chancellors and Principals
(Beardsley 1984). As described below, it was however strongly influenced by the way decision
making was undertaken by its director.
Until July 1978,whenGMAGachieved full legal status, itsmemberswereboundby theOfficial Secrets
Act. After this date, its members were covered by section 28 of the Health and Safety and Work Act
(1974), a provision that allows disclosure of the committees business if health is at risk (Lewin 1977).
Throughout the70’sGMAGmangedto retainanarrowfocusontechnical issuesand laboratorysafety.
The chairman of the House of Commons select committee on Science and technology, Arthur Palmer
stated ‘it is very surprising that the Genetic Manipulation Advisory Group (GMAG) has not been asked
to consider thewider aspects of this important new science’. Towhich the acting head of theGMAGdel-
egation, Professor Mark Richmond responded ‘early in our meetings we agreed we would not address
eitherthescientificmeritofresearchproposalsorthesocial ramificationsofthescience’. Thenewscientist
reports that ‘MPs were visibly shaken at Richmonds remarks’ (Anonymous 1978a, 915).
In 1978, initiated by Sydney Brenner and developed by various subcommittees, GMAG proposed a
new Risk Assessment Scheme, which they hoped would be adopted by Europe in preference to NIH
controls. While unions in the UK remained committed to GMAG controls (Dickson 1978), the scheme
was rejected by private industry (the CBI pressing for parity with NIH), the EMBO and received only a
cool response from other European countries. Wright (1994) suggests that the European response
coloured its reception in the UK Scientists feared that complying with GMAG would mean overzea-
lous safety committees, unnecessary delays and costs (Wright 1994).
GMAG was coming under pressure to relax controls in line with the US. William Henderson
became the new chair of GMAG in January 1979. He promised scientists fewer delays and faced
down the unions, refusing to allow the union time to consult with their constituents. This was
quite different to the previous chairman, Gordon Wolstenholme who tended to wait for the
unions to consult (Wright 1994). Controls were somewhat relaxed, and by March 1979 the risk assess-
ment scheme included criteria for categorisation that was very close to NIH guidelines.
The Royal Society and the Committee on Genetic Experimentation (COGENE), in April 1979, jointly
sponsored an international conference on recombinant DNA, held at Wye College, Kent. Various
notable characters and characters from the American story were in attendance including Maxine
Singer, Stanley Cohen and James Watson. The April COGENE Royal Society meeting left no doubt
that the Americans intended to dismantle their controls over recombinant DNA technology, with
support of the NIH (Wright 1996). The continued closed nature of policy making in the UK on the
other hand, was a talking point. Professor Robert Hugh Pritchard spoke about scientist perceptions
of regulatory policy making:
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While I have been impressed by the evidence of such a dialogue in the United States, there has been no such
dialogue in Britain. There is no mechanism for such a dialogue. I do not know how GMAG reaches its decision
because they are arrived at with all the openness of a papal enclave. (Pritchard, 1979, cited by Morgan and
Whelan 2013, 226)
Europe ultimately diverged from the direction set by the US, pursuing a process rather product
based evaluation of GMOs (Dunlop 2000). GMAG was replaced by the Advisory Committee on
Genetic Manipulation (ACGM) in 1984, a committee that reported to the HSE, that had employers
and employee representatives, but no public interest groups (Beardsley 1984). The unions were
however, an important group which briefly, but strongly influenced the direction of GMAG up
until 1978.
The general trend internationally towards the end of the 1970s was to follow the NIH model. 1979
saw the conservative government gaining power, a trend towards deregulation and the prioritisa-
tion of biotechnology as a promising new industry. Regulatory control over genetic manipulation
was now seen as more stringent in the UK to the point at which it might be thought of as detrimental
to economic growth and prosperity. GMAG was gradually dismantled and the last of its functions
were transferred to the health and safety executive in 1984 (Wright 1994).
The end of the 1970s saw the establishment of the biotechnology industry in the UK. Leading
molecular geneticists situated in Europe at this time largely operated out of university laboratories,
they continued to be an intrinsic part of the academic community. Their spaces were carefully regu-
lated and monitored by the mechanisms of oversight that came into being as a result of the small
pox outbreaks in 1973 and 1978. They quietly went about their experiments, rarely gaining admit-
tance past the closed doors that marked off the various committees in charge of writing regulation
and policy. This is perhaps in contrast to molecular biologists and private interests in the US.
5. Conclusion: epistemic cultures and resistance to change
The story of regulation in US and the UK show a number of similarities. In both cases in the initial
stages, policy making amidst uncertainty drew upon the expertise of the practitioners at the fore-
front of the science. Policy making occurred in a relatively closed group, with decisions being
made without wide consultation and experts changing practice at the laboratory level in response
to perceived concerns.
In the UK however, a very early framing of risk that tended more towards individualism was insti-
gated by the Robens report. Mitigating apathy would be done through a system of self-regulation
which would see the burden of risk management falling on employers and workers. In this initial
framing of risk, wider society and its concerns were shut out of the debate, a theme which is
shown to recur for example with GMAG later manging to retain a narrow focus on technical
issues and laboratory safety.
In the US, discussions around the epidemic pathogen were foregrounded and the epistemic
machinery – the methods, tools and techniques, changed in anticipation of this general risk to
the public. In the UK however, the experts drawn into policy making had already been impacted
by the smallpox incident of 1973 and the resulting code of practice that was widely implemented
in 1974. The micropractices of laboratories changed in response to a proven risk of a different
nature – a risk that singularly affected laboratory staff.
With risks framed and experienced in this way in the UK, the involvement of the trade unions as
worker representatives was inevitable. The unions were central to the debate until the change of
government in 1979 and under Wolstenholme’s GMAG chairmanship. This in addition to the
closed nature of debate and consultation is likely responsible for the continued narrow framing of
risk and the focus on the safety of laboratory workers.
There was contestation over regulatory space with the HSE and the Williams report offering ways
forward. As Grundmann (1996) observes, the epistemic community continued to exist and work
despite the conflict. The configuration of the regulatory space, shaped by the strong influences of
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experts and their experiences, continued to resist change until the much stronger forces of dereg-
ulation and the prioritisation of biotechnology as a promising new industry in an international
landscape.
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